ATE416159T1 - Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält - Google Patents

Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält

Info

Publication number
ATE416159T1
ATE416159T1 AT03794249T AT03794249T ATE416159T1 AT E416159 T1 ATE416159 T1 AT E416159T1 AT 03794249 T AT03794249 T AT 03794249T AT 03794249 T AT03794249 T AT 03794249T AT E416159 T1 ATE416159 T1 AT E416159T1
Authority
AT
Austria
Prior art keywords
oral solid
medicinal product
solid medicinal
crystal
dysuria
Prior art date
Application number
AT03794249T
Other languages
English (en)
Inventor
Eiji Tsuru
Michio Toda
Kazuma Hirata
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31973150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE416159(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Application granted granted Critical
Publication of ATE416159T1 publication Critical patent/ATE416159T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
AT03794249T 2002-09-06 2003-09-05 Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält ATE416159T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002262157 2002-09-06

Publications (1)

Publication Number Publication Date
ATE416159T1 true ATE416159T1 (de) 2008-12-15

Family

ID=31973150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03794249T ATE416159T1 (de) 2002-09-06 2003-09-05 Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält

Country Status (24)

Country Link
US (1) US20060142374A1 (de)
EP (1) EP1541554B1 (de)
JP (1) JP4532274B2 (de)
KR (1) KR100670592B1 (de)
CN (1) CN1321111C (de)
AT (1) ATE416159T1 (de)
AU (1) AU2003264385B2 (de)
BR (1) BR0314338A (de)
CA (1) CA2496780C (de)
DE (1) DE60325074D1 (de)
ES (1) ES2316858T3 (de)
HK (1) HK1084396A1 (de)
HR (1) HRP20050214B1 (de)
IL (1) IL167168A (de)
IS (1) IS2640B (de)
MX (1) MXPA05002549A (de)
NO (2) NO329855B1 (de)
NZ (1) NZ538598A (de)
PL (1) PL375701A1 (de)
RU (1) RU2347774C2 (de)
TW (1) TW200407126A (de)
UA (1) UA78854C2 (de)
WO (1) WO2004022538A1 (de)
ZA (1) ZA200501884B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0317349A (pt) * 2002-12-16 2005-11-16 Kissei Pharmaceutical Droga sólida para uso oral
CN1930123B (zh) * 2004-03-05 2010-06-23 橘生药品工业株式会社 用于预防或治疗伴有神经障碍的膀胱过度活动症的医药组合物
EP1800677A4 (de) * 2004-10-05 2008-04-02 Kissei Pharmaceutical Mittel zur prävention und/oder behandlung von harnsammelstörungen im zusammenhang mit obstruktion der unteren harnwege
ATE535242T1 (de) * 2004-10-06 2011-12-15 Kissei Pharmaceutical Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie
EP1838326A4 (de) * 2005-02-02 2009-09-30 Teva Pharma Verfahren zur herstellung von polypeptidmischungen mittels hydrogenolyse
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
DK2101569T3 (da) * 2006-12-14 2012-01-30 Teva Pharma Krystallinsk fast rasagilinbase
WO2008106125A2 (en) * 2007-02-26 2008-09-04 Concert Pharmaceuticals, Inc. Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
US20100076010A1 (en) * 2007-02-26 2010-03-25 Concert Pharmaceuticals, Inc. Alpha 1a-adrenoceptor antagonists
MX2009009230A (es) * 2007-02-28 2009-11-26 Kissei Pharmaceutical Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
ES2471076T3 (es) 2010-06-28 2014-06-25 Ratiopharm Gmbh Compuestos de inclusión de silodoxina-ciclodextrina
JP2013532651A (ja) 2010-07-23 2013-08-19 ラティオファルム ゲー・エム・ベー・ハー シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品
WO2012014186A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Process for the preparation of silodosin and its novel intermediates
CN102229557B (zh) * 2010-08-05 2013-03-27 南京海纳医药科技有限公司 西洛多辛的半水合物晶体、制备方法和包含它的药物组合物
CN102229558B (zh) * 2010-08-05 2013-05-08 南京海纳医药科技有限公司 西洛多辛的晶型δ、它的制备方法和包含它的药物组合物
CN102010359B (zh) * 2010-09-10 2013-01-23 北京阳光诺和药物研究有限公司 β晶型西洛多辛的制备方法
WO2012077138A1 (en) 2010-12-09 2012-06-14 Panacea Biotec Limited Methods of crystallizing (r) -1- (3 -hydroxypropyl) -5- [2- [2- [2- ( 2, 2, 2 - trifluoroethoxy) phenoxy] ethylamino] propyl] indoline-7 -carboxamide
PL2474529T3 (pl) * 2010-12-23 2014-10-31 Sandoz Ag Formy krystaliczne farmaceutycznej substancji czynnej
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
WO2013061338A1 (en) * 2011-08-24 2013-05-02 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
WO2013072935A2 (en) 2011-10-10 2013-05-23 Cadila Healthcare Limited Process for the preparation of silodosin
CN105142633A (zh) * 2013-03-26 2015-12-09 橘生药品工业株式会社 西洛多辛苦味被掩蔽的口服给药制剂
CN103159664B (zh) * 2013-03-29 2016-03-23 深圳市海滨制药有限公司 一种赛洛多辛原料药及其制备方法、药物组合物
WO2015015512A2 (en) * 2013-07-29 2015-02-05 Ind-Swift Laboratories Limited Process for the preparation of silodosin and its gamma form
JP2015117192A (ja) * 2013-12-17 2015-06-25 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
US9643921B2 (en) 2014-02-06 2017-05-09 Ube Industries, Ltd. Method for producing indoline compound
KR20150127996A (ko) * 2014-05-08 2015-11-18 한미정밀화학주식회사 실로도신 감마형 결정의 제조방법
KR101725393B1 (ko) * 2014-07-24 2017-04-27 주식회사 경보제약 실로도신의 제조 방법 및 신규 중간체
KR101673160B1 (ko) 2014-10-24 2016-11-07 보령제약 주식회사 실로도신 γ 결정형의 제조방법
JP2016147811A (ja) * 2015-02-10 2016-08-18 ダイト株式会社 シロドシンγ型結晶の製造方法
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
KR101733084B1 (ko) 2016-07-27 2017-05-08 (주)다산메디켐 실로도신의 결정형의 제조방법
EP3354283B1 (de) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische kapselzusammensetzung mit silodosin
JP2018035199A (ja) * 2017-12-07 2018-03-08 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
CN107903201B (zh) * 2017-12-27 2020-09-25 浙江天宇药业股份有限公司 一种β晶型西洛多辛的制备方法
CN111410626B (zh) * 2019-01-04 2022-11-04 上海汇伦医药股份有限公司 赛洛多辛α-晶型的制备方法
CN109824569B (zh) * 2019-04-04 2022-09-20 重庆医药高等专科学校 一种西罗多辛晶型i及其制备方法
WO2020237643A1 (zh) * 2019-05-31 2020-12-03 上海汇伦生命科技有限公司 赛洛多辛α-晶型的制备方法
CN114601826A (zh) * 2022-03-31 2022-06-10 乐泰药业有限公司 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69319551T2 (de) * 1992-12-02 1998-10-29 Kissei Pharmaceutical Indolin Verbindungen zur Behandlung von Dysurien
JP3331048B2 (ja) * 1994-06-01 2002-10-07 キッセイ薬品工業株式会社 インドール誘導体
WO1999015202A1 (fr) * 1997-09-22 1999-04-01 Kissei Pharmaceutical Co., Ltd. Medicaments contre la dysurie resultant d'une hypertrophie de la prostate
WO1999048530A1 (en) * 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
JP4921646B2 (ja) * 2001-03-08 2012-04-25 キッセイ薬品工業株式会社 １−（３−ベンジルオキシプロピル）−５−（２−置換プロピル）インドリン誘導体およびその使用方法
ES2362788T3 (es) * 2004-10-27 2011-07-13 Kissei Pharmaceutical Co., Ltd. Compuesto de indolina y proceso para la producción del mismo.

Also Published As

Publication number Publication date
MXPA05002549A (es) 2005-06-03
CA2496780A1 (en) 2004-03-18
EP1541554A4 (de) 2006-11-08
CA2496780C (en) 2011-03-15
BR0314338A (pt) 2005-07-05
NO329855B1 (no) 2011-01-10
WO2004022538A1 (ja) 2004-03-18
HRP20050214A2 (en) 2006-05-31
EP1541554A1 (de) 2005-06-15
TW200407126A (en) 2004-05-16
TWI305148B (de) 2009-01-11
NO2011011I1 (no) 2011-07-25
ZA200501884B (en) 2006-05-31
US20060142374A1 (en) 2006-06-29
KR100670592B1 (ko) 2007-01-17
EP1541554B1 (de) 2008-12-03
AU2003264385A1 (en) 2004-03-29
RU2347774C2 (ru) 2009-02-27
HRP20050214B1 (hr) 2013-09-30
NZ538598A (en) 2007-08-31
HK1084396A1 (en) 2006-07-28
IS7785A (is) 2005-04-05
PL375701A1 (en) 2005-12-12
CN1694867A (zh) 2005-11-09
JP4532274B2 (ja) 2010-08-25
AU2003264385B2 (en) 2009-12-17
JPWO2004022538A1 (ja) 2005-12-22
CN1321111C (zh) 2007-06-13
DE60325074D1 (de) 2009-01-15
KR20050057181A (ko) 2005-06-16
NO20051709L (no) 2005-06-06
NO2011011I2 (de) 2012-10-01
IS2640B (is) 2010-06-15
IL167168A (en) 2010-11-30
RU2005109930A (ru) 2006-01-20
ES2316858T3 (es) 2009-04-16
UA78854C2 (en) 2007-04-25

Similar Documents

Publication Publication Date Title
ATE416159T1 (de) Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält
ATE264337T1 (de) Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
DE59402222D1 (de) Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ATE202346T1 (de) Benzofuran derivate und ihre verwendung als inhibitoren der knochenresorption
MX9700763A (es) Procedimiento para la preparacion de benzoxazoles y derivados de piridinas utiles en el tratamiento de la diabetes del tipo ii, los benzoxazoles y derivados de piridina obtenidos, composiciones de los mismos y su uso.
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
NO20082445L (no) Neuropeptid-2 reseptor-agonister
ATE453617T1 (de) Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
HK1075894A1 (en) Prucalopride-n-oxide
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
DE60035177D1 (de) Arzneimittel für trockene haut
TH28860A (th) สารประกอบชนิดใหม่

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties